Forteo (generic name teriparatide) is an Eli Lilly drug which the company website ststes is "approved for use in both men and postmenopausal women with osteoporosis who are at high risk for having fractures. FORTEO can be used by people who have had a fracture related to osteoporosis, or who have multiple risk factors for fracture or who cannot use other osteoporosis treatments." 
The global launch of the drug was in 2002.
In the 2006 calendar year Eli Lilly earned $US594.3 million in revenue from Forteo, $416.2 million of which was from sales in the US and $178.1 million elsewhere in the world. This, according to Eli Lilly's 2006 annual report, was an increased in sales of 53% over the previous year's global sales of $US389.3 million.  (2.3MB Pdf) In its annual report Lilly stated that "U.S. sales signi?cantly bene?ted from patients' access to medical coverage through the Medicare Part D program and from decreased utilization of our U.S. patient assistance program, LillyAnswers. Sales outside the U.S. increased 43 percent, re?ecting a strong demand."
Other SourceWatch Resources
Drug Company's Website
Eli Lilly Media Releases
- "03-May-2006 FORTEO® (teriparatide injection) reimbursement update: May 2006", Media Release, May 3, 2006.
- "Eli Lilly Australia disappointed with PBAC decision to not recommend Forteo for the PBS", Media release, December 15, 2006.
- "Eli Lilly Becomes First to Use New FTA Measure to Appeal PBS Rejection for Forteo", Global Insight, undated, accessed February 2007.
- Simon Lauder, "US drug company appeals PBS decision", The World Today, ABC Radio National, May 8, 2006.
- Mark Metherell, "Drug subsidy appeal to test new review", Sydney Morning Herald, May 8, 2006.
- "Pharmaceutical company uses US FTA to push for review of PBS listing", AFTINET Bulletin, May 12, 2006.
|This article is a stub. You can help by expanding it.|